Good morning, everyone, and how are you today? We are doing just fine, thank you. A comfortable breeze is wafting through the Pharmalot campus, where our short person still has a few days to sleep in and our official mascot is stalking the grounds in search of chipmunks. As for us, we are engaging in the usual ritual of brewing cups of stimulation. The neurons can use all the help they can get. Meanwhile, here are a few items of interest to jump start your own day. We hope all goes well today and, of course, do stay safe. …

The Trump administration is asking states to speed up approval for Covid-19 vaccine distribution sites by Nov. 1, the latest sign the federal government is eager to get a vaccine out before the end of the year, The Wall Street Journal writes. Centers for Disease Control and Prevention Director Robert Redfield urged state governors to remove barriers to building permits for distribution sites for use by McKesson (MCK). The wholesaler has a deal with the federal government to distribute a Covid-19 vaccine when it becomes available.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy